Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.48 |
| ▸ | CTSB | P07858 | 4/20 | 0.48 |
| ▸ | CTSV | O60911 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24938630 | 1.00 | CTSL (0.48) | CTSLCTSBCTSVCTSSCTSK | |
| SCHEMBL30277102 | 1.00 | CTSL (0.48) | CTSLCTSBCTSVCTSSCTSK | |
| SCHEMBL24938631 | 1.00 | CTSL (0.48) | CTSLCTSBCTSVCTSSCTSK | |
| SCHEMBL30276973 | 0.89 | CTSL (0.48) | CTSLCTSBCTSVCTSSCTSK | |
| SCHEMBL24710026 | 0.89 | CTSL (0.48) | CTSLCTSBCTSVCTSSCTSK | |
| SCHEMBL24939086 | 0.86 | CTSL (0.51) | CTSLCTSBCTSVCTSSCTSK | |
| SCHEMBL30276961 | 0.85 | CTSB (0.49) | CTSBCTSS | |
| SCHEMBL24710011 | 0.85 | CTSB (0.49) | CTSBCTSS | |
| SCHEMBL25855483 | 0.85 | CTSB (0.49) | CTSBCTSS | |
| SCHEMBL30277094 | 0.83 | CTSL (0.49) | CTSLCTSBCTSVCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4352040-A1 | PROTEASE INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | The Scripps Research Institute (US) | 2024-04-17 | — | — | EP | claimed |
| WO-2022261473-A1 | PROTEASE INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-12-15 | — | — | WO | claimed |
| EP-4352040-A1 | PROTEASE INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | The Scripps Research Institute (US) | 2024-04-17 | — | — | EP | disclosed |
| US-11708348-B2 | Protease inhibitors for treatment of coronavirus infections | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-07-25 | — | — | US | disclosed |
| WO-2022261473-A1 | PROTEASE INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708348-B2 | Protease inhibitors for treatment of coronavirus infections | ACE, ACE2, TMPRSS2 | CTSL 19/4885CTSB 15/4885CTSV 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.